Article Summary
A published case report from the National Allergy Centre, India, described the management of five patients with chronic rhinosinusitis (with or without nasal polyps) and co-morbid asthma who were sensitized to Alternaria alternata. The report evaluated a combination of Alternaria alternata subcutaneous allergen immunotherapy (SCIT) and omalizumab. Over a one-year assessment period, the five patients showed improvement in symptom-control scores, lung-function measurements, and selected immunological parameters. The authors reported that the combined approach was well tolerated in these cases and allowed patients to reach maintenance immunotherapy doses.
What Is Chronic Rhinosinusitis?
Chronic rhinosinusitis is an inflammatory condition affecting the nose and paranasal sinuses that persists for at least 12 weeks. The case report describes symptoms such as nasal obstruction, facial pain or pressure, reduced sense of smell, and mucopurulent nasal drainage, together with objective evidence of inflammation. Chronic rhinosinusitis can occur with nasal polyps (CRSwNP) or without nasal polyps (CRSsNP).
The report also highlights the frequent coexistence of chronic rhinosinusitis and asthma. It notes that inflammatory pathways and allergic sensitization may contribute to the relationship between upper and lower airway disease.
The Role of Alternaria alternata
Alternaria alternata is a common environmental fungus and an important source of fungal aeroallergens. The report describes it as an allergen found both indoors and outdoors and associates sensitization with allergic rhinitis and severe asthma with fungal sensitization.
The paper identifies Alt a 1 as a predominant allergen associated with Alternaria sensitization. Because Alternaria is widespread in the environment, complete avoidance can be difficult. The authors therefore discuss practical measures such as reducing dampness, dust and debris, addressing moisture-related problems in buildings, and avoiding indoor smoking to help reduce conditions that support fungal growth.
What Was Studied?
Five patients with chronic rhinosinusitis and co-morbid asthma were treated with a combination of Alternaria alternata subcutaneous allergen immunotherapy and omalizumab. Two patients had chronic rhinosinusitis with nasal polyps, while three had chronic rhinosinusitis without nasal polyps.
The patients underwent allergy assessment that included skin prick testing and measurement of specific IgE. The treatment protocol used gradual dose escalation of Alternaria allergen extract to reach a maximum tolerated maintenance dose. Omalizumab was administered at 150 mg, with the reported schedule varying by case. Two patients received the combined treatment for two years, while three received it for one year.
How Were the Patients Assessed?
The report assessed outcomes using several clinical and laboratory measures. These included the Rhinitis Control Assessment Test (RCAT), Asthma Control Test (ACT), Sino-nasal Outcome Test-22 (SNOT-22), peak expiratory flow rate (PEFR), specific IgE and total IgE measurements, eosinophil counts, and endoscopic or radiographic findings where applicable.
Across the five cases, the authors reported improvement in rhinitis and asthma control scores, a reduction in SNOT-22 scores, improved PEFR variability, and reductions in the ratio of specific IgE to total IgE for Alternaria alternata.
Reported Outcomes
After approximately one year of treatment, all five patients were reported to have responded well. The case report states that the patients became asymptomatic or had substantially better-controlled nasal and respiratory symptoms and remained under follow-up.
The authors reported that the specific-IgE-to-total-IgE ratio for Alternaria decreased in all five cases: from 4.1% to 2.24% in Case 1, 2.5% to 0.24% in Case 2, 5.5% to 1.7% in Case 3, 3.9% to 1.25% in Case 4, and 1.67% to 0.5% in Case 5. The report also describes an approximately 50% reduction in skin-test reactivity.
The clinical scoring results also showed improvement. RCAT scores increased in all five cases, indicating better reported rhinitis control, while ACT scores increased, indicating improved reported asthma control. SNOT-22 scores decreased, reflecting improvement in reported sino-nasal symptoms and quality-of-life measures.
Why Is This Combination of Interest?
Allergen immunotherapy is intended to modify the immune response to a specific allergen over time. Omalizumab is an anti-IgE medicine that reduces free IgE and affects IgE-mediated allergic responses. The report discusses the possibility that combining anti-IgE treatment with allergen-specific immunotherapy may provide complementary effects.
In these five cases, the authors reported that the combination was associated with a faster and sustained build-up of allergen immunotherapy, a favorable safety profile, and improvement in clinical and laboratory measures. However, the authors also noted that double-blind, placebo-controlled trials of this combined approach are rare and that further research is needed before the treatment can be recommended broadly for patients with these conditions.
Key Takeaways
- Alternaria alternata is an environmental fungal allergen that may be relevant in allergic respiratory disease.
- Chronic rhinosinusitis and asthma can occur together and may involve overlapping inflammatory and allergic pathways.
- The published case report evaluated five patients treated with Alternaria alternata allergen immunotherapy combined with omalizumab.
- The five patients showed reported improvements in rhinitis, asthma and sino-nasal symptom scores, along with changes in selected immunological measures.
- The findings come from a small case series, so they should be interpreted as clinical observations rather than proof that the combination is effective for all patients.
- Allergen testing and treatment decisions should be made by an appropriately qualified allergy or respiratory specialist.
Important Note
This article is an educational summary of a published case report and is not a substitute for individual medical advice, diagnosis or treatment. Omalizumab and allergen immunotherapy require appropriate clinical assessment and supervision. Patients should discuss their symptoms, allergy testing and treatment options with a qualified healthcare professional.
Source
Kathuria PC, Rai M, Rai D (2021). Successful management by Combination of Alternaria alternata Subcutaneous Allergen Immunotherapy with Omalizumab in five cases of Chronic Rhinosinusitis with or without Nasal Polyps Co-morbid Asthma. JSM Clinical Case Reports, 9(1):1182.










